MedTrace Logo

Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810

NCT03260179 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-08-24

No results posted yet for this study

Summary

This project intends to make a study of personalized medicine evaluation system establishment for liver cancer, gastric cancer and nasopharynx cancer to provide strong support for the development of Precision Medicine and personalized medicine for the patients of high-incidence-rates cancer in China.

Conditions

  • Advanced Solid Tumor
  • Advanced/Metastatic Colorectal Cancer

Interventions

DRUG

AL3810

Fasting，oral ，4w on or 3w on/1w off

DRUG

AL3810

Fasting，oral ，4w on or 3w on/1w off

DRUG

AL3810

Fasting，oral ，4w on or 3w on/1w off

Sponsors & Collaborators

  • Shanghai Institute of Materia Medica, Chinese Academy of Sciences

    collaborator OTHER

  • Haihe Biopharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-31
Primary Completion
2019-01-31
Completion
2019-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03260179 on ClinicalTrials.gov